H1 2023 Financial Highlights

Rare Disease Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN PRIMARY ENDPOINT(S) STATUS IPN 60250 Phase II NCT05642468 10mg IPN60250 tablet QD for 12 weeks Primary sclerosing cholangitis 12 Treatment-related adverse events Recruiting1 30mg (3x10 mg) IPN60250 tablets QD for 12 weeks Elafibranor ELMWOOD Phase II NCT05627362 Primary sclerosing cholangitis IPN 60260 Phase I ISRCTN13265717 IPSEN Innovation for patient care 60 60 Placebo or elafibranor Viral cholestatic 108 disease Interventional Safety, significant changes in physical examination findings, laboratory parameters, vital signs, electrocardiogram readings Recruiting1 To be confirmed Recruiting¹ 1. Recruitment status as per ct.gov, June 2023. QD: once a day. 30

View entire presentation